RNAC

RNAC EBITDA Margin

-10671.90%TTM

Period ending:

RNAC FY EBITDA Margin%
RNAC FY EBITDA Margin3712.85%-34288.68%
2014-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

RNAC ebitda margin history

EBITDA as a percentage of revenue. The available annual fiscal periods series contains 12 observations from Dec 31, 2014 to Dec 31, 2025.

Cartesian Therapeutics Inc EBITDA Margin — Annual fiscal periods
Period endingEBITDA Margin
-4,881.5159%
-195.2715%
-903.8379%
35.2853%
-6.6117%
-401.193%
-775.8574%
-6,962.0155%
-30,611.1111%
-422.5535%
-385.6596%
-377.1053%

Compare ebitda margin

All RNAC financial metrics · RNAC stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.